IAGX Dr. Reddy's Launches Celadrin as a Pharmaceutical Product in India
Dr. Reddy's Launches Celadrin as a Pharmaceutical Product in India
SAN DIEGO
Imagenetix, Inc., San Diego
Patrick Millsap, 858-674-8455
V.P. Marketing
Imagenetix, Inc. (OTCBB: IAGX), www.imagenetix.net, the developer of Celadrin(R), a proprietary fatty acid complex useful in promoting joint health, announced today that it has formed a partnership with Cymbiotics, Inc., a San Diego, Calif.-based company, and Dr. Reddy's Laboratories (NYSE: RDY), a major pharmaceutical company in Hyderabad, India, to launch Celadrin to physicians treating patients with osteoarthritis in India. Celadrin has been approved for use as a pharmaceutical product in India to help reduce pain and inflammation in patients with joint conditions. In the United States, Celadrin is currently available in oral form as a dietary supplement and as an over-the-counter topical cream at food, drug and mass retail stores.
Bill Spencer, CEO of Imagenetix, said: "Celadrin is a proprietary fatty acid complex that has been clinically shown to promote joint health with no known or reported side effects. We are pleased that Dr. Reddy's, a public traded New York Stock Exchange company, is introducing Celadrin to doctors and consumers throughout India."
According to Satish Reddy, Managing Director and COO of Dr. Reddy's: "Dr. Reddy's is emerging as the partner of choice for many innovators in healthcare because of our strong brand equity and extensive reach in the Indian market. Celadrin will enhance the treatment options available to medical practitioners in India, and we will be marketing the product in capsule and topical cream forms."
Celadrin has been shown to be safe and effective in several double-blind, placebo-controlled clinical studies. In one such study conducted at the University of Connecticut, subjects with knee joint conditions who used Celadrin in cream form showed significant improvement in quality of life measurements such as getting up from a seated position and stair climbing. A similar study determined that patients who took Celadrin orally improved knee range of motion and overall function. Both studies were published in the prestigious Journal of Rheumatology. Participants in the studies exhibited no side effects.
About Imagenetix
San Diego-based Imagenetix, Inc. (Symbol: IAGX), www.imagenetix.net, is an innovator of scientifically tested, natural-based, proprietary bioceutical products that enhance human health. The company develops, formulates and private-labels, proprietary over-the-counter topical creams, skin care products, nutritional supplements and pharmaceutical compounds to be marketed globally through multiple channels of distribution.
About Dr. Reddy's
Dr. Reddy's Laboratories (NYSE: RDY), www.drreddys.com, is a global, vertically integrated pharmaceutical company with a presence across the value chain, producing and delivering safe, innovative, and high quality finished dosage forms, active pharmaceutical ingredients and biotechnology products which are marketed in more than 100 countries.
About Cymbiotics
Cymbiotics, Inc., based in San Diego, Calif. (USA), is a bio-pharmaceutical company that designs, develops, validates and introduces innovative disease-specific formulations in pain management, cardiovascular disease, periodontal disease, urinary incontinence and other inflammation management-related conditions. For more information, visit www.cymbiotics.net.
Safe Harbor Statement
This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are subject to risks and uncertainties that could cause actual results to vary materially from those projected in the forward-looking statements. The company may experience significant fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services. These factors and others could cause operating results to vary significantly from those in prior periods and those projected in forward-looking statements. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in certain forms the company expects to file with the Securities Exchange Commission.
